Table 3 Reasons for change of anti-retroviral therapy regimens
Antiretroviral therapy regimens (number of participants who had regimen changed) and reasons for change of regimens | Number of participants who had their regimens changed per categories of the reasons of change (%)a |
|---|---|
Zidovudine + lamivudine + nevirapine (n = 43) | |
Stock out | 43 (100%) |
Tenofovir + lamivudine + nevirapine (n = 20) | |
Stock out | 20 (100%) |
Stavudine + lamivudine + nevirapine (n = 53) | |
Stock out | 39 (73.6%) |
Tuberculosis | 4 (7.5%) |
Peripheral neuropathy | 4 (7.5%) |
Lipodystrophy | 3 (5.7%) |
Pregnancy | 3 (5.7%) |
Zidovudine + lamivudine + efavirenz (n = 10) | |
Stock out | 10 (100%) |
Tenofovir + lamivudine + efavirenz (n = 2) | |
Stock out | 1 (50%) |
Anemia | 1 (50%) |
Tenofovir + emcitrabine + efavirenz (n = 1) | 1 |
Stock out | 1 (100%) |